These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1880231)

  • 21. Pharmacokinetic parameters of ceftriaxone after single intravenous and intramuscular administration in camels (Camelus Dromedarius).
    Goudah A
    Res Vet Sci; 2008 Jun; 84(3):483-9. PubMed ID: 17765938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of caffeine on ceftriaxone disposition and plasma protein binding in the rat.
    Kwon KI; Bourne DW
    J Pharmacokinet Biopharm; 1986 Aug; 14(4):397-408. PubMed ID: 3689487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients.
    Muder RR; Agarwala S; Mirani A; Gayowski T; Venkataramanan R
    J Clin Pharmacol; 2002 Jun; 42(6):644-50. PubMed ID: 12043952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of ketoprofen in rats: effect of age and dose.
    Satterwhite JH; Boudinot FD
    Biopharm Drug Dispos; 1992 Apr; 13(3):197-212. PubMed ID: 1576328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis.
    Ti TY; Fortin L; Kreeft JH; East DS; Ogilvie RI; Somerville PJ
    Antimicrob Agents Chemother; 1984 Jan; 25(1):83-7. PubMed ID: 6322683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Explaining the poor bacteriologic eradication rate of single-dose ceftriaxone in group a streptococcal tonsillopharyngitis: a reverse engineering solution using pharmacodynamic modeling.
    Blumer JL; Reed MD; Kaplan EL; Drusano GL
    Pediatrics; 2005 Oct; 116(4):927-32. PubMed ID: 16199703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide.
    Giacomini KM; Swezey SE; Turner-Tamiyasu K; Blaschke TF
    J Pharmacokinet Biopharm; 1982 Feb; 10(1):1-14. PubMed ID: 7069575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Ceftriaxone in malignant occlusive jaundice. Studies of serum and bile concentration in disordered bile excretion].
    Maikowski C; Rösch W; Sörgel F
    Fortschr Med; 1993 Nov; 111(32):513-6. PubMed ID: 8294078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of intravenous azithromycin and ceftriaxone when administered alone and concurrently to healthy volunteers.
    Chiu LM; Menhinick AM; Johnson PW; Amsden GW
    J Antimicrob Chemother; 2002 Dec; 50(6):1075-9. PubMed ID: 12461037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of plasma and free tissue levels of ceftriaxone in rats by microdialysis.
    Kovar A; Dalla Costa T; Derendorf H
    J Pharm Sci; 1997 Jan; 86(1):52-6. PubMed ID: 9002459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of probenecid on the elimination and protein binding of ceftriaxone.
    Stoeckel K; Trueb V; Dubach UC; McNamara PJ
    Eur J Clin Pharmacol; 1988; 34(2):151-6. PubMed ID: 3383987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-dose ceftriaxone kinetics in liver insufficiency.
    Stoeckel K; Tuerk H; Trueb V; McNamara PJ
    Clin Pharmacol Ther; 1984 Oct; 36(4):500-9. PubMed ID: 6090050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Age and ceftriaxone kinetics.
    Luderer JR; Patel IH; Durkin J; Schneck DW
    Clin Pharmacol Ther; 1984 Jan; 35(1):19-25. PubMed ID: 6317271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis.
    Losno Garcia R; Santivañez V; Battilana CA
    Chemotherapy; 1988; 34(4):261-6. PubMed ID: 3208543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Salicylate clearance, the resultant of protein binding and metabolism.
    Furst DE; Tozer TN; Melmon KL
    Clin Pharmacol Ther; 1979 Sep; 26(3):380-9. PubMed ID: 466931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical pharmacokinetics of ceftriaxone.
    Yuk JH; Nightingale CH; Quintiliani R
    Clin Pharmacokinet; 1989 Oct; 17(4):223-35. PubMed ID: 2686882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single-dose ceftriaxone kinetics in functionally anephric patients.
    Stoeckel K; McNamara PJ; Hoppe-Seyler G; Blumberg A; Keller E
    Clin Pharmacol Ther; 1983 May; 33(5):633-41. PubMed ID: 6301740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis.
    Zhao Y; Cudkowicz ME; Shefner JM; Krivickas L; David WS; Vriesendorp F; Pestronk A; Caress JB; Katz J; Simpson E; Rosenfeld J; Pascuzzi R; Glass J; Rezania K; Harmatz JS; Schoenfeld D; Greenblatt DJ
    J Clin Pharmacol; 2014 Oct; 54(10):1180-7. PubMed ID: 24771634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pharmacokinetics of ceftriaxone in hemodialysis].
    Laville M; Mercatello A; Freney J; Pozet N; Meugnier H; Labeeuw M; Fleurette J; Zech P
    Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):719-23. PubMed ID: 3309803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and protein binding of ceftriaxone during pregnancy.
    Bourget P; Fernandez H; Quinquis V; Delouis C
    Antimicrob Agents Chemother; 1993 Jan; 37(1):54-9. PubMed ID: 8431018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.